Premium
INDORAMIN IN ESSENTIAL HYPERTENSION: A SURVEY OF THE PATIENT RECORDS FROM LONG‐TERM CLINICAL TRIALS
Author(s) -
JOHNSON E.S.
Publication year - 1981
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1981.tb00308.x
Subject(s) - medicine , blood pressure , sedation , diastole , hydrochlorothiazide , diuretic , anesthesia , thiazide
1 The results of seven long‐term clinical trials of indoramin in patients with essential hypertension were analysed by the scatter diagram method which allowed the comparison of each experimental point with a theoretical predetermined response line. The method consisted of constructing a scatter diagram of fall in diastolic blood pressure against pretreatment diastolic blood pressure for all patients after 3 and 12 months' treatment with indoramin. 2 The decrease in blood pressure caused by indoramin given continuously for 12 months was not significantly different from that caused by the drug after only 3 months of treatment. This indicates that indoramin's antihypertensive effect did not diminish during long‐term therapy with the drug. By the scatter diagram analysis about 60% patients had ‘excellent’ responses (less than 90 mm Hg diastolic blood pressure) to indoramin alone or with a thiazide diuretic, 25% had ‘good’ responses (between 90 and 100 mm Hg diastolic blood pressure) and 15% had ‘poor’ responses (greater than 100 mm Hg diastolic blood pressure). 3 The principal side‐effects were sedation, dry mouth, dizziness and, in male patients, failure of ejaculation. These side‐effects were reported by each patient suffering them on average on between 1.3 and 1.8 occasions only. Reporting diminished as the trials progressed. Some investigators noted that side‐effects were occasionally reversed by moderate reduction in indoramin dosage.